Gianluca Del Conte
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers.
Journal: Future oncology (London, England)
Published: October 18, 2025
Total and Regional Changes in Body Composition in Metastatic Hormone-sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide ± Zoledronic Acid. The BONENZA Study.
Journal: European urology oncology
Published: December 16, 2024
Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial.
Journal: Prostate cancer and prostatic diseases
Published: November 17, 2024
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 06, 2024
Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide.
Journal: European urology
Published: March 10, 2024
A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma.
Journal: JHEP reports : innovation in hepatology
Published: July 06, 2023
Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma.
Journal: Neuro-oncology advances
Published: November 16, 2022
Erratum to 'Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors': [ESMO Open Volume 7, Issue 2, April 2022, 100447].
Journal: ESMO open
Published: July 16, 2022
Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial.
Journal: Cancer immunology, immunotherapy : CII
Published: March 19, 2021
Renal Function Assessment Gap in Clinical Practice: An Awkward Truth.
Journal: Kidney & blood pressure research
Published: September 10, 2019
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
Journal: Targeted oncology
Published: October 26, 2017
Last Updated: 09/26/2026